Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)

Technology appraisal guidance
Reference number: TA23
Published: 26 April 2001
Last updated: 03 March 2016

History

Documents created during the development process.

Review proposal consultation

Review proposal consultation
Stakeholder matrix (PDF 104 KB)

Published:

07 January 2016
Review proposal paper (PDF 240 KB)

Published:

07 January 2016

Other information

TA23 Brain cancer - temozolomide: summary
TA23 Brain cancer - temozolomide: summary (PDF 42 KB)

Published:

04 November 2002

Background information

TA23 Brain cancer - temozolomide: review decision - May 2011 information
Appendix A: decision paper presented to the Institute's Guidance Executive
Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 63 KB)

Published:

11 May 2011
Review decision information
TA23 Brain cancer - temozolomide: HTA report information
TA23 Brain cancer - temozolomide: HTA report (PDF 312 KB)

Published:

27 April 2001
TA23 Brain cancer - temozolomide: review proposal - March 2011 information
Appendix A: provisional matrix of stakeholders
Appendix A: provisional matrix of stakeholders (PDF 18 KB)

Published:

25 March 2011
Appendix B: proposal paper presented to the Institute's Guidance Executive
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 231 KB)

Published:

25 March 2011